HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Murad files lawsuit against Strawberry.net

This article was originally published in The Rose Sheet

Executive Summary

Dermatologist-developed skin-care firm has filed a U.S. federal court lawsuit against the owners and operators of Strawberrynet.com, a Hong Kong-based website, for diverting and selling defaced Murad products, the El Segundo, Calif.-based company announces June 3. Strawberry.net, which has no authorized relationship with Murad, is selling more than 80 products from nine of the company's lines, as of the filing date of the suit. In its filing, the firm alleges that the Murad products sold on the site have been defaced and stripped of quality-control tracking features including hologram protection seals and unique batch codes used for tracking and protecting the public from counterfeit goods and health risks. Murad is sold through retailers worldwide including Sephora, Ulta and Massage Envy, as well as at numerous spas and salons
Advertisement
Advertisement
UsernamePublicRestriction

Register

RS016992

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel